Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2019.1847
Abstract: Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. Objective To determine whether adding… read more here.
Keywords: pfs; egfr mutant; trial; erlotinib ... See more keywords
Time-staggered delivery of erlotinib and doxorubicin by gold nanocages with two smart polymers for reprogrammable release and synergistic with photothermal therapy.
Sign Up to like & getrecommendations! Published in 2019 at "Biomaterials"
DOI: 10.1016/j.biomaterials.2019.119327
Abstract: Photochemotherapy is currently an effective anticancer therapy. Recently, it has been reported that cancer cells pretreated with epidermal growth factor receptor (EGFR) inhibitor erlotinib (Erl) can significantly synergize its apoptosis against the DNA damaging agent… read more here.
Keywords: time staggered; erlotinib; therapy; photothermal therapy ... See more keywords
Physical blood‐brain barrier disruption induced by focused ultrasound does not overcome the transporter‐mediated efflux of erlotinib
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Controlled Release"
DOI: 10.1016/j.jconrel.2018.11.009
Abstract: &NA; Overcoming the efflux mediated by ATP–binding cassette (ABC) transporters at the blood‐brain barrier (BBB) remains a challenge for the delivery of small molecule tyrosine kinase inhibitors (TKIs) such as erlotinib to the brain. Inhibition… read more here.
Keywords: disruption; fus; erlotinib; bbb disruption ... See more keywords
Polymorphs and hydrates of the anticancer drug erlotinib: X-ray crystallography, phase transition and biopharmaceutical studies
Sign Up to like & getrecommendations! Published in 2021 at "CrystEngComm"
DOI: 10.1039/d1ce00032b
Abstract: Erlotinib, a non-small cell lung cancer BCS class II drug, was found to occur as two polymorphs and two hydrates depending on the crystallization conditions. The monohydrate (form III), which has been reported in patents… read more here.
Keywords: form; polar solvents; form iii; erlotinib ... See more keywords
Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway
Sign Up to like & getrecommendations! Published in 2017 at "Bioscience Reports"
DOI: 10.1042/bsr20160478
Abstract: Recent evidence supports a role for microRNA-223 (miR-223) in modulating tumor cell sensitivity to chemotherapeutic drugs; however, its role in cellular resistance to the effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) used… read more here.
Keywords: hcc827 cells; hcc827; erlotinib; expression ... See more keywords
Multifunctional magnetic nanoparticles for MRI-guided co-delivery of erlotinib and L-asparaginase to ovarian cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Microencapsulation"
DOI: 10.1080/02652048.2022.2094487
Abstract: Abstract The use of magnetic nanoparticles (MNPs) in biomedical applications has been wildly opted due to their unique properties. Here, we designed MNPs loaded with erlotinib (ERL/SPION-Val-PEG) and conjugated them with anti-mucin16 (MUC16) aptamer to… read more here.
Keywords: ovarian cancer; asparaginase; erlotinib; magnetic nanoparticles ... See more keywords
Identification of Ketene-Reactive Intermediate of Erlotinib Possibly Responsible for Inactivation of P450 Enzymes
Sign Up to like & getrecommendations! Published in 2018 at "Drug Metabolism and Disposition"
DOI: 10.1124/dmd.117.079327
Abstract: Erlotinib (ELT), a tyrosine kinase inhibitor, is widely used for the treatment of nonsmall cell lung cancer in clinic. Unfortunately, severe drug-induced liver injury and other adverse effects occurred during the treatment. Meanwhile, ELT has… read more here.
Keywords: inactivation; erlotinib; p450; intermediate ... See more keywords
Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.9006
Abstract: 9006Background: Development of treatment for EGFR-mutated non-small-cell lung cancer (NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. Combinations of EGFR-TKIs and VEGF inhibitors are one of candidates for next strategy for EGFR-mutated… read more here.
Keywords: egfr mutations; study comparing; erlotinib; phase iii ... See more keywords
A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib Study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.6054
Abstract: 6054 Background: When combined with COX-2 inhibitors, the EGFR tyrosine kinase inhibitor Erlotinib has shown a better antitumor response in preclinical studies. Since high volume hospitals in many countries usually have a longer waiting period… read more here.
Keywords: oral squamous; combination; treatment; erlotinib ... See more keywords
A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Gastrointestinal Oncology"
DOI: 10.21037/jgo-22-327
Abstract: Background Epidermal growth factor receptor (EGFR) is overexpressed in pancreatic cancer. EGFR expression plays a potentially important role in modulation of tumor sensitivity to either chemotherapy or radiotherapy. Erlotinib is a receptor tyrosine kinase inhibitor… read more here.
Keywords: pancreatic cancer; therapy; trial; phase trial ... See more keywords
Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.939118
Abstract: Translational Relevance Evaluation of targeted therapies is urgently needed for the majority of patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) who progress after immunochemotherapy. Erlotinib, a targeted inhibitor of epidermal growth factor… read more here.
Keywords: tumor response; smoking status; erlotinib; treatment ... See more keywords